iShares Genomics Immunology and Healthcare ETF IDNA

Morningstar Medalist Rating

Morningstar’s Analysis IDNA

Will IDNA outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

iShares Genomics Immnlgy & Hlthcr ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings IDNA

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings51.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Moderna Inc

13.7547M
Healthcare

Genmab AS

6.0320M
Healthcare

Twist Bioscience Corp

4.7116M
Healthcare

Regeneron Pharmaceuticals Inc

4.3915M
Healthcare

Bayer AG

4.3615M
Healthcare

Takeda Pharmaceutical Co Ltd

4.1114M
Healthcare

Exelixis Inc

3.8213M
Healthcare

Merck & Co Inc

3.5712M
Healthcare

Vertex Pharmaceuticals Inc

3.5212M
Healthcare

Incyte Corp

3.4512M
Healthcare

Sponsor Center